Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 May 2004, Vol. 103, No. 9, pp. 3544-3546.
Prepublished online as a Blood First Edition Paper on December 11, 2003; DOI 10.1182/blood-2003-07-2441.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2003-07-2441v1
103/9/3544    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Armstrong, S. A.
Right arrow Articles by Korsmeyer, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Armstrong, S. A.
Right arrow Articles by Korsmeyer, S. J.
Related Collections
Right arrow Neoplasia
Right arrow Oncogenes and Tumor Suppressors
Right arrow Signal Transduction
Right arrow Gene Expression
Right arrow Brief Reports
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

NEOPLASIA
Brief report

FLT3 mutations in childhood acute lymphoblastic leukemia

Scott A. Armstrong, Meghann E. Mabon, Lewis B. Silverman, Aihong Li, John G. Gribben, Edward A. Fox, Stephen E. Sallan, and Stanley J. Korsmeyer

From the Departments of Pediatric Oncology, Adult Oncology and Cancer Immunology and AIDS, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA; Division of Hematology/Oncology, Children's Hospital, Boston, MA; and the Howard Hughes Medical Institute, Boston, MA.

Activating mutations of the FLT3 receptor tyrosine kinase are common in acute myelogenous leukemia (AML) but are rare in adult acute lymphoblastic leukemia (ALL). We have recently shown that FLT3 is highly expressed and often mutated in ALLs with rearrangement of the mixed lineage leukemia (MLL) gene on chromosome 11q23. Because hyperdiploid ALL samples also show high-level expression of FLT3, we searched for the presence of FLT3 mutations in leukemic blasts from 71 patients with ALL. The data show that approximately 25% (6 of 25) of hyperdiploid ALL samples possess FLT3 mutations, whereas only 1 of 29 TEL/AML1-rearranged samples harbored mutations (P = .04, Fisher exact test). Three mutations are novel in-frame deletions within a 7-amino acid region of the receptor juxtamembrane domain. Finally, 3 samples from patients whose disease would relapse harbored FLT3 mutations. These data suggest that patients with hyperdiploid or relapsed ALL might be considered candidates for therapy with newly described small-molecule FLT3 inhibitors. (Blood. 2004;103: 3544-3546)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
J. W. Tyner, M. W. Deininger, M. M. Loriaux, B. H. Chang, J. R. Gotlib, S. G. Willis, H. Erickson, T. Kovacsovics, T. O'Hare, M. C. Heinrich, et al.
RNAi screen for rapid therapeutic target identification in leukemia patients
PNAS, May 26, 2009; 106(21): 8695 - 8700.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. Kearney, D. Gonzalez De Castro, J. Yeung, J. Procter, S. W. Horsley, M. Eguchi-Ishimae, C. M. Bateman, K. Anderson, T. Chaplin, B. D. Young, et al.
Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia
Blood, January 15, 2009; 113(3): 646 - 648.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Case, E. Matheson, L. Minto, R. Hassan, C. J. Harrison, N. Bown, S. Bailey, J. Vormoor, A. G. Hall, and J. A.E. Irving
Mutation of Genes Affecting the RAS Pathway Is Common in Childhood Acute Lymphoblastic Leukemia
Cancer Res., August 15, 2008; 68(16): 6803 - 6809.
[Abstract] [Full Text] [PDF]


Home page
J Natl Cancer Inst MonogrHome page
J. Wiemels
Chromosomal Translocations in Childhood Leukemia: Natural History, Mechanisms, and Epidemiology
J Natl Cancer Inst Monographs, July 1, 2008; 2008(39): 87 - 90.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
X.-F. Huang, S.-K. Luo, J. Xu, J. Li, D.-R. Xu, L.-H. Wang, M. Yan, X.-R. Wang, X.-B. Wan, F.-M. Zheng, et al.
Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia
Blood, March 1, 2008; 111(5): 2854 - 2865.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
R. W. Stam, M. L. den Boer, P. Schneider, M. Meier, H. B. Beverloo, and R. Pieters
D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia
Haematologica, November 1, 2007; 92(11): 1565 - 1568.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. Kiyoi, Y. Shiotsu, K. Ozeki, S. Yamaji, H. Kosugi, H. Umehara, M. Shimizu, H. Arai, K. Ishii, S. Akinaga, et al.
A Novel FLT3 Inhibitor FI-700 Selectively Suppresses the Growth of Leukemia Cells with FLT3 Mutations
Clin. Cancer Res., August 1, 2007; 13(15): 4575 - 4582.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. Akasaka, T. Balasas, L. J. Russell, K.-j. Sugimoto, A. Majid, R. Walewska, E. L. Karran, D. G. Brown, K. Cain, L. Harder, et al.
Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL)
Blood, April 15, 2007; 109(8): 3451 - 3461.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
O. Piloto, B. Nguyen, D. Huso, K.-T. Kim, Y. Li, L. Witte, D. J. Hicklin, P. Brown, and D. Small
IMC-EB10, an Anti-FLT3 Monoclonal Antibody, Prolongs Survival and Reduces Nonobese Diabetic/Severe Combined Immunodeficient Engraftment of Some Acute Lymphoblastic Leukemia Cell Lines and Primary Leukemic Samples.
Cancer Res., May 1, 2006; 66(9): 4843 - 4851.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
D. Small
FLT3 Mutations: Biology and Treatment
Hematology, January 1, 2006; 2006(1): 178 - 184.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Chiaretti, X. Li, R. Gentleman, A. Vitale, K. S. Wang, F. Mandelli, R. Foa, and J. Ritz
Gene Expression Profiles of B-lineage Adult Acute Lymphocytic Leukemia Reveal Genetic Patterns that Identify Lineage Derivation and Distinct Mechanisms of Transformation
Clin. Cancer Res., October 15, 2005; 11(20): 7209 - 7219.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. W. Stam, M. L. den Boer, P. Schneider, P. Nollau, M. Horstmann, H. B. Beverloo, E. van der Voort, M. G. Valsecchi, P. de Lorenzo, S. E. Sallan, et al.
Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia
Blood, October 1, 2005; 106(7): 2484 - 2490.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. A. Armstrong and A. T. Look
Molecular Genetics of Acute Lymphoblastic Leukemia
J. Clin. Oncol., September 10, 2005; 23(26): 6306 - 6315.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. Grundler, C. Miething, C. Thiede, C. Peschel, and J. Duyster
FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model
Blood, June 15, 2005; 105(12): 4792 - 4799.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. Brown, M. Levis, S. Shurtleff, D. Campana, J. Downing, and D. Small
FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression
Blood, January 15, 2005; 105(2): 812 - 820.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. M. Stone, D. J. DeAngelo, V. Klimek, I. Galinsky, E. Estey, S. D. Nimer, W. Grandin, D. Lebwohl, Y. Wang, P. Cohen, et al.
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
Blood, January 1, 2005; 105(1): 54 - 60.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
C.-H. Pui, M. Schrappe, R. C. Ribeiro, and C. M. Niemeyer
Childhood and Adolescent Lymphoid and Myeloid Leukemia
Hematology, January 1, 2004; 2004(1): 118 - 145.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020